<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3CF9EB25-5323-4160-9802-0B125921F055"><gtr:id>3CF9EB25-5323-4160-9802-0B125921F055</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>McRae</gtr:otherNames><gtr:surname>Allan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DC247267-DA2E-47CD-838A-348F17241C68"><gtr:id>DC247267-DA2E-47CD-838A-348F17241C68</gtr:id><gtr:firstName>Nancy</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Rothwell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/06387C6B-1B86-443A-84A3-B49FA39E384B"><gtr:id>06387C6B-1B86-443A-84A3-B49FA39E384B</gtr:id><gtr:firstName>Emmanuel</gtr:firstName><gtr:surname>Pinteaux</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801296"><gtr:id>29575790-CA0A-4753-B70C-2EE4BC10855F</gtr:id><gtr:title>Mechanisms of interleukin-1 action in neuronal injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801296</gtr:grantReference><gtr:abstractText>The blood supply to the brain provides essential oxygen and nutrients to support brain function. During stroke, haemorrhage (bleeding), head injury and certain types of dementia, the blood supply to the brain may be partially reduced or blocked, with fatal consequences for the patient. Our work focuses on understanding what happens in the brain and the rest of the body when the blood supply is reduced, in order to develop safer and more effective treatments for stroke. We have discovered that, in animal brains, a molecule normally associated with inflammation and infection (called interleukin-1 or IL-1 for short) increases when the blood supply is blocked. IL-1 can then kill brain cells, most importantly the nerve cells (neurones), which are essential for the brain to work properly. Our work in animals has already led to the testing of a drug that blocks the effects of IL-1 in stroke patients. However, to develop successful treatments for stroke and other conditions, we need to better understand how IL-1 kills brain cells either directly or by releasing killer molecules from other brain cells. We will test our discoveries in relevant animal models of disease and are well placed to take these findings into patients. This work may lead to new ways of blocking IL-1 and possible new treatments for stroke and related diseases.</gtr:abstractText><gtr:technicalSummary>Cerebral ischaemia is one of the leading causes of death and disability worldwide. It occurs in stroke, sub-arachnoid and intra-cerebral haemorrhage, brain trauma, surgery and tumours, birth asphyxia and vascular dementia. Despite its devastating consequences there are few, if any, effective treatments, and a history of hundreds of failed trials. These failures may be for a number of reasons, including the choice of targets, animal models (which fail to replicate human pathology), and poor recognition that cerebral ischaemia is heavily dependent on processes occurring within the vasculature. The programme addresses these concerns and builds on our record of discovery in cerebral ischaemia. We have demonstrated the importance of central nervous system inflammation and the contribution of the pro-inflammatory cytokine interleukin-1 (IL-1) to experimental brain injury, and conducted a Phase II trial of IL-1 receptor antagonist in acute stroke. 
Our overall objective is to fully elucidate the mechanisms of IL-1 action in neuronal injury and to optimise new targets for the treatment of cerebral ischaemia. More specifically, within this programme of work we will:
I. Identify how IL-1 acts on astrocytes and endothelial cells to cause neuronal injury
II. Determine how IL-1 modifies neuronal susceptibility to injury
III. Translate findings to identify and validate new targets and interventions in CI
The proposed studies will use a combination of molecular, cellular and in vivo approaches, to not only identify the downstream mediators of IL-1 action, but also the interplay between the multiple cellular effects of IL-1 that we have identified to date. All in vitro findings will be validated in vivo in animal models of ischaemic brain injury. We will then take forward identified interventions, which show significant neuroprotection, for further validation as potential treatments.
This programme of translational research will relate closely to our ongoing clinical studies. We have extensive published and preliminary data supporting our hypotheses, established techniques and very experienced research staff.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>754131</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>World Stroke Day 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>2033CE39-43BD-4F81-908E-00E4B81B1D23</gtr:id><gtr:impact>World Stroke Day event in Oct. 2011 organised by our clinical colleagues. The clinical investigator Dr Tyrrell presented the results of the clinical study funded by this grant. The audience comprised ~180 stroke patients and their carers, healthcare professionals and associated charities/organisations.

Not known.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Stroke Day 2011</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>373F08AE-187A-45A3-B98A-169E1FE76BC1</gtr:id><gtr:impact>Had several interactive stands/displays showing different aspects of our preclinical research, at World Stroke Day event in Oct. 2011 organised by our clinical colleagues. The audience comprised ~180 stroke patients and their carers, healthcare professionals and associated charities/organisations.

Not known.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote talk at Stroke Assembly</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BD78FB6A-2877-4484-83F5-DBB321AF4635</gtr:id><gtr:impact>An annual event that enables stroke survivors and their families to express their opinions and hopes in a UK-wide forum. This was held in 2013 at Nottingham University. Around 200 people attended and participated in discussions around our research.

Not yet known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.strokeassembly.org.uk/content/brains-fire</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at the University of Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AF61EE42-A83F-4138-A387-5B3CB1520CA2</gtr:id><gtr:impact>Talk title: &amp;quot;A stroke of bad luck: mechanisms and treatments for brain disease&amp;quot;. For ~200 Uni staff and students. Followed by questions and discussion.

No specific impact known.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Numerous scientific, public and policy talks - too many to detail</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>67823954-68F0-4EBF-8217-817377FACEFE</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frontiers of Science talk, Uni of Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>663C1381-6C3D-48F4-AE8E-1A227B650A3C</gtr:id><gtr:impact>Frontiers of Science talk delivered to ~150 undergraduate students from 1st year to 3rd year, followed by questions and discussion. 
Title: &amp;quot;Flaming brains - new discoveries about brain disease&amp;quot;


No specific impact known.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote lecture to Schools Science Conference 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>80B7ACE4-26A9-4D50-ADD1-518356523CA6</gtr:id><gtr:impact>Talk followed by Q&amp;amp;A session. Title: &amp;quot;A stroke of bad luck - new discoveries in the treatment of brain disease&amp;quot;. Session: Science is the Future.
Venue : Royal College of Pathologists, London
Audience : 50 secondary year students from years 10-13 and their teachers

No specific impact known.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>A086A8B1-97B1-438F-AB8D-336B3222015E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>113000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/13/55/30365</gtr:fundingRef><gtr:id>2F42BE3C-64B7-4ED0-8DFF-862054E03B0D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transgenic mice generated for conditional deletion of interleukin-1 type1 and type2 receptors, to study the role of IL-1 in inflammation. These mice are currently named as key tools in current grant applications.</gtr:description><gtr:id>4FC48920-E80F-42B4-9379-32F58E8A1F76</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Generation of IL-1R1 and IL-1R2 floxed mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88B230F3-E05E-497D-874E-90B4CB4AE5E2"><gtr:id>88B230F3-E05E-497D-874E-90B4CB4AE5E2</gtr:id><gtr:title>Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52f0b8c9472f54ba05dcf384dbc7ea9c"><gtr:id>52f0b8c9472f54ba05dcf384dbc7ea9c</gtr:id><gtr:otherNames>Allen C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9AED361-0F39-4C87-ADFC-348602FAD2B7"><gtr:id>F9AED361-0F39-4C87-ADFC-348602FAD2B7</gtr:id><gtr:title>Characterization of a conditional interleukin-1 receptor 1 mouse mutant using the Cre/LoxP system.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da815d16666956367a40d61684afbaf8"><gtr:id>da815d16666956367a40d61684afbaf8</gtr:id><gtr:otherNames>Abdulaal WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4289ADB0-C4E9-4559-B093-33DCA972002A"><gtr:id>4289ADB0-C4E9-4559-B093-33DCA972002A</gtr:id><gtr:title>Activation of brain endothelial cells by interleukin-1 is regulated by the extracellular matrix after acute brain injury.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a48ed91020521b8348a360d0bb784aff"><gtr:id>a48ed91020521b8348a360d0bb784aff</gtr:id><gtr:otherNames>Summers L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53BBC0BC-654E-403A-A4BF-E15BBCF01ADA"><gtr:id>53BBC0BC-654E-403A-A4BF-E15BBCF01ADA</gtr:id><gtr:title>The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/768e31d265f5cf02b5282ca2bc6c9773"><gtr:id>768e31d265f5cf02b5282ca2bc6c9773</gtr:id><gtr:otherNames>Rodriguez-Grande B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CD01547D-BD88-41F7-9379-11846DA300F1"><gtr:id>CD01547D-BD88-41F7-9379-11846DA300F1</gtr:id><gtr:title>Interleukin-1 drives cerebrovascular inflammation via MAP kinase-independent pathways.</gtr:title><gtr:parentPublicationTitle>Current neurovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dd02fd254ff5c1ab0efc233b3f8f0b5"><gtr:id>3dd02fd254ff5c1ab0efc233b3f8f0b5</gtr:id><gtr:otherNames>Thornton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1567-2026</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B7C8F1B-EA43-4CC5-81B9-A6EA1B14FEC6"><gtr:id>6B7C8F1B-EA43-4CC5-81B9-A6EA1B14FEC6</gtr:id><gtr:title>Expanding Biosensing Abilities through Computer-Aided Design of Metabolic Pathways.</gtr:title><gtr:parentPublicationTitle>ACS synthetic biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/47a4db172a7b5a11612d29271a5394bc"><gtr:id>47a4db172a7b5a11612d29271a5394bc</gtr:id><gtr:otherNames>Libis V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2161-5063</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6905BE20-F8DA-465A-8592-170C4FCC0CCE"><gtr:id>6905BE20-F8DA-465A-8592-170C4FCC0CCE</gtr:id><gtr:title>IL-1 signaling is critical for expansion but not generation of autoreactive GM-CSF+ Th17 cells.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f4f9218f0033303e64f22cd07b9d88a"><gtr:id>9f4f9218f0033303e64f22cd07b9d88a</gtr:id><gtr:otherNames>Mufazalov IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1E37F48-D089-4658-920E-8C893B4FF030"><gtr:id>F1E37F48-D089-4658-920E-8C893B4FF030</gtr:id><gtr:title>Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the Mammalian Central Nervous System.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82767c202b56a42005a3630bcf84edda"><gtr:id>82767c202b56a42005a3630bcf84edda</gtr:id><gtr:otherNames>Bruttger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5814B384-BA21-4EDD-B374-38D2EA4347E4"><gtr:id>5814B384-BA21-4EDD-B374-38D2EA4347E4</gtr:id><gtr:title>Platelet interleukin-1alpha drives cerebrovascular inflammation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dd02fd254ff5c1ab0efc233b3f8f0b5"><gtr:id>3dd02fd254ff5c1ab0efc233b3f8f0b5</gtr:id><gtr:otherNames>Thornton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/06159D18-6080-4340-8B52-A8AD72F4EAF6"><gtr:id>06159D18-6080-4340-8B52-A8AD72F4EAF6</gtr:id><gtr:title>The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/768e31d265f5cf02b5282ca2bc6c9773"><gtr:id>768e31d265f5cf02b5282ca2bc6c9773</gtr:id><gtr:otherNames>Rodriguez-Grande B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A7DFFFE-E2A1-4485-B405-564C84D7CA89"><gtr:id>5A7DFFFE-E2A1-4485-B405-564C84D7CA89</gtr:id><gtr:title>Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/841e09ddfb965c1f148f94d852b8403c"><gtr:id>841e09ddfb965c1f148f94d852b8403c</gtr:id><gtr:otherNames>Denes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30B89079-D332-4255-A3DF-D8D9B552D452"><gtr:id>30B89079-D332-4255-A3DF-D8D9B552D452</gtr:id><gtr:title>Generation of a Novel T Cell Specific Interleukin-1 Receptor Type 1 Conditional Knock Out Mouse Reveals Intrinsic Defects in Survival, Expansion and Cytokine Production of CD4 T Cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f4f9218f0033303e64f22cd07b9d88a"><gtr:id>9f4f9218f0033303e64f22cd07b9d88a</gtr:id><gtr:otherNames>Mufazalov IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C598901A-91AF-4E08-BD50-E052C22F4967"><gtr:id>C598901A-91AF-4E08-BD50-E052C22F4967</gtr:id><gtr:title>Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [&amp;sup1;8F]-IL1RA and PET imaging in rats.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2f466dc8e256d603f888c16a293004e3"><gtr:id>2f466dc8e256d603f888c16a293004e3</gtr:id><gtr:otherNames>Cawthorne C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/234C1F8A-D09A-4D05-849B-D40133D64D22"><gtr:id>234C1F8A-D09A-4D05-849B-D40133D64D22</gtr:id><gtr:title>Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e52c68665ac793cddb61c05192bf59e5"><gtr:id>e52c68665ac793cddb61c05192bf59e5</gtr:id><gtr:otherNames>Greenhalgh AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2416822B-1D5D-4C3E-A5F0-BD1214D1994E"><gtr:id>2416822B-1D5D-4C3E-A5F0-BD1214D1994E</gtr:id><gtr:title>AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/841e09ddfb965c1f148f94d852b8403c"><gtr:id>841e09ddfb965c1f148f94d852b8403c</gtr:id><gtr:otherNames>Denes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0DAC6E39-55FB-41F8-9285-8A87A0C446F8"><gtr:id>0DAC6E39-55FB-41F8-9285-8A87A0C446F8</gtr:id><gtr:title>Neuronal Toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4308542640b569b83f41b6e1b701a83f"><gtr:id>4308542640b569b83f41b6e1b701a83f</gtr:id><gtr:otherNames>Leow-Dyke S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801296</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>